A study done to find out how well triamcinolone acetonide, pentoxifylline, and the two of them together help in growing hair back after being injected into areas where alopecia areata has caused hair loss.
Phase 2
- Conditions
- Health Condition 1: L639- Alopecia areata, unspecified
- Registration Number
- CTRI/2024/03/064833
- Lead Sponsor
- Vinayak Viswanath
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Clinically and dermoscopically diagnosed patients with single or multiple patches of alopecia areata
Exclusion Criteria
1.Non-consenting patients
2.Patients with alopecia affecting more than 50% of scalp
3.Any treatment taken for alopecia in the past one month.
4.Prior history of allergic reactions to pentoxifylline, triamcinolone, or injection adjuvants or components
5.Pregnant and lactating females
6.Localised infection at injection site.
7.Known case of HIV, Hepatitis B and Hepatitis C or any other immune-compromised disease
8.Patient on systemic steroids or any other immunosuppressive treatment.
9. Acute febrile or any other bacterial infection.
10.Asthma, allergic skin disorder, history of convulsions
11.Bleeding disorders.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method